Development of a Sendai virus vector-based AIDS vaccine inducing T cell responses

@article{Seki2016DevelopmentOA,
  title={Development of a Sendai virus vector-based AIDS vaccine inducing T cell responses},
  author={Sayuri Seki and Tetsuro Matano},
  journal={Expert Review of Vaccines},
  year={2016},
  volume={15},
  pages={119 - 127}
}
Virus-specific CD8+ T-cell responses play a major role in the control of HIV replication, and induction of HIV-specific T-cell responses is an important strategy for AIDS vaccine development. Optimization of the delivery system and immunogen would be the key for the development of an effective T cell-based AIDS vaccine. Heterologous prime-boost vaccine regimens using multiple viral vectors are a promising protocol for efficient induction of HIV-specific T-cell responses, and the development of… 
The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector
TLDR
This review outlines approaches for developing vaccines against the new SARS-CoV-2 coronavirus that are based on non-pathogenic viral vectors, since it can be administered intranasally and induce a mucosal immune response that strengthens the antiviral barrier in the respiratory tract and provides reliable protection against infection.
The Profile of T Cell Responses in Bacille Calmette–Guérin-Primed Mice Boosted by a Novel Sendai Virus Vectored Anti-Tuberculosis Vaccine
TLDR
The data strongly suggest that the enhanced immune protection induced by SeV85AB boosting was associated with establishment of an increased capacity to recall antigen-specific IL-2-mediated T cell responses and confirms this Sendai virus vector system as a promising candidate to be used in a heterologous prime-boost immunization regimen against TB.
Sendai Virus, a Strong Inducer of Anti-Lentiviral State in Ovine Cells
TLDR
Observations may boost new approximations in ameliorating the SRLV burden by stimulation of the innate immune response using SeV-based vaccine vectors.
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens
TLDR
The first-in-human safety and immunogenicity assessment of a prototype intranasally administered, replication-competent Sendai virus (SeV)–vectored, human immunodeficiency virus type 1 (HIV-1) vaccine primed functional, durable HIV-specific T-cell responses and boosted antibody responses.
Avian Paramyxovirus Type-3 as a Vaccine Vector: Identification of a Genome Location for High Level Expression of a Foreign Gene
TLDR
APMV-3 could be a more useful vaccine vector for avian pathogens than NDV, and the insertion of GFP gene into the P-M gene junction resulted in higher level of expression of G FP than when the gene was inserted into the upstream N-P gene junction.

References

SHOWING 1-10 OF 100 REFERENCES
Antigen-specific T-cell induction by vaccination with a recombinant Sendai virus vector even in the presence of vector-specific neutralizing antibodies in rhesus macaques.
TLDR
The feasibility of inducing antigen-specific T-cell responses by SeV vaccination even in the host with pre-existing anti-SeV neutralizing antibodies is suggested.
An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants
TLDR
An AIDS vaccine based on attenuated VSV vectors expressing env and gag genes and tested it in rhesus monkeys, finding protection from AIDS was highly significant.
Control of Simian Immunodeficiency Virus Replication by Vaccine-Induced Gag- and Vif-Specific CD8+ T Cells
TLDR
The results suggest that replication of the AIDS virus can be controlled by vaccine-induced subdominant Gag/Vif epitope-specific CD8+ T cells, providing a rationale for the induction of Gag- and/or Vif-specific T-cell responses by prophylactic AIDS vaccines.
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
TLDR
The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine and elicited by a replication-incompetent Ad5 vector, used either alone or as a booster inoculation after priming with a DNA vector.
Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus
TLDR
These studies suggest a safe strategy for the enhanced generation of T-cell-mediated protective immunity to HIV-1, and a consecutive immunization strategy involving priming with DNA and boosting with rFPV vaccines encoding common HIV- 1 antigens is evaluated.
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
TLDR
The protective efficacy of vaccine-elicited immune responses against a pathogenic SHIV-89.6P challenge in rhesus monkeys is reported, with no evidence of clinical disease or mortality after challenge.
Novel approaches in polyepitope T-cell vaccine development against HIV-1
TLDR
The authors will focus on construction and rational design of polyepitope T-cell HIV-1 immunogens and their delivery, including advantages and disadvantages of existing T- cell epitope prediction methods.
Cytotoxic T Lymphocyte–based Control of Simian Immunodeficiency Virus Replication in a Preclinical AIDS Vaccine Trial
TLDR
Evidence is shown suggesting that vaccine-induced CTLs control SIVmac239 replication in rhesus macaques and results indicate that vaccine induction of highly effective C TLs can result in the containment of replication of a highly pathogenic immunodeficiency virus.
A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus.
TLDR
It is demonstrated that AAV-HIV vector immunization may provide a novel and promising HIV vaccination strategy.
Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies.
TLDR
The potential of intranasal SeV vector vaccination to induce CD8(+) T-cell responses even in humans is implied, suggesting a rationale for proceeding to a vaccine clinical trial using this vector.
...
1
2
3
4
5
...